The Centers for Disease Control and Prevention and US Preventive Services Task Force recommend one-time hepatitis C virus (HCV) testing for persons born during 1945-1965 (birth cohort). However, few studies estimate the effect of birth cohort (BC) testing implementation on HCV diagnoses in primary care settings. We aimed to determine the probability of identifying HCV infections in primary care using targeted BC testing compared with usual care at three academic medical centers. From December 2012 to March 2014, each center compared one of three distinct interventions with usual care using an independently designed randomized controlled trial. Across centers, BC patients with no clinical documentation of previous HCV testing or diagnosis were randomly assigned to receive a one-time offering of HCV antibody (anti-HCV) testing via one of three independent implementation strategies (repeated-mailing outreach, electronic medical record-integrated provider best practice alert [BPA], and direct patient solicitation) or assigned to receive usual care. We estimated model-adjusted risk ratios (aRR) of anti-HCV-positive (anti-HCV+) identification using BC testing versus usual care. In the repeated mailing trial, 8992 patients (intervention, n = 2993; control, n = 5999) were included in the analysis. The intervention was eight times as likely to identify anti-HCV+ patients compared with controls (aRR, 8.0; 95% confidence interval [CI], 2.8-23.0; adjusted probabilities: intervention, 0.27%; control, 0.03%). In the BPA trial, data from 14,475 patients (BC, n = 8928; control, n = 5,547) were analyzed. The intervention was 2.6 times as likely to identify anti-HCV+ patients versus controls (aRR, 2.6; 95% CI, 1.1-6.4; adjusted probabilities: intervention, 0.29%; control, 0.11%). In the patient-solicitation trial, 8873 patients (BC, n = 4307; control, n = 4566) were analyzed. The intervention was five times as likely to identify anti-HCV+ patients compared with controls (aRR, 5.3; 95% CI, 2.3-12.3; adjusted probabilities: intervention, 0.68%; control, 0.11%). Conclusion: BC testing was effective in identifying previously undiagnosed HCV infections in primary care settings. (Hepatology 2018;67:524-533).
RCT Entities:
The Centers for Disease Control and Prevention and US Preventive Services Task Force recommend one-time hepatitis C virus (HCV) testing for persons born during 1945-1965 (birth cohort). However, few studies estimate the effect of birth cohort (BC) testing implementation on HCV diagnoses in primary care settings. We aimed to determine the probability of identifying HCV infections in primary care using targeted BC testing compared with usual care at three academic medical centers. From December 2012 to March 2014, each center compared one of three distinct interventions with usual care using an independently designed randomized controlled trial. Across centers, BC patients with no clinical documentation of previous HCV testing or diagnosis were randomly assigned to receive a one-time offering of HCV antibody (anti-HCV) testing via one of three independent implementation strategies (repeated-mailing outreach, electronic medical record-integrated provider best practice alert [BPA], and direct patient solicitation) or assigned to receive usual care. We estimated model-adjusted risk ratios (aRR) of anti-HCV-positive (anti-HCV+) identification using BC testing versus usual care. In the repeated mailing trial, 8992 patients (intervention, n = 2993; control, n = 5999) were included in the analysis. The intervention was eight times as likely to identify anti-HCV+ patients compared with controls (aRR, 8.0; 95% confidence interval [CI], 2.8-23.0; adjusted probabilities: intervention, 0.27%; control, 0.03%). In the BPA trial, data from 14,475 patients (BC, n = 8928; control, n = 5,547) were analyzed. The intervention was 2.6 times as likely to identify anti-HCV+ patients versus controls (aRR, 2.6; 95% CI, 1.1-6.4; adjusted probabilities: intervention, 0.29%; control, 0.11%). In the patient-solicitation trial, 8873 patients (BC, n = 4307; control, n = 4566) were analyzed. The intervention was five times as likely to identify anti-HCV+ patients compared with controls (aRR, 5.3; 95% CI, 2.3-12.3; adjusted probabilities: intervention, 0.68%; control, 0.11%). Conclusion: BC testing was effective in identifying previously undiagnosed HCV infections in primary care settings. (Hepatology 2018;67:524-533).
Authors: Philip R Spradling; Loralee Rupp; Anne C Moorman; Mei Lu; Eyasu H Teshale; Stuart C Gordon; Cynthia Nakasato; Joseph A Boscarino; Emily M Henkle; David R Nerenz; Maxine M Denniston; Scott D Holmberg Journal: Clin Infect Dis Date: 2012-08-08 Impact factor: 9.079
Authors: Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki Journal: N Engl J Med Date: 2011-03-31 Impact factor: 91.245
Authors: Anne C Moorman; Stuart C Gordon; Loralee B Rupp; Philip R Spradling; Eyasu H Teshale; Mei Lu; David R Nerenz; Cynthia C Nakasato; Joseph A Boscarino; Emily M Henkle; Nancy J Oja-Tebbe; Jian Xing; John W Ward; Scott D Holmberg Journal: Clin Infect Dis Date: 2012-09-18 Impact factor: 9.079
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: David R Nelson; James N Cooper; Jacob P Lalezari; Eric Lawitz; Paul J Pockros; Norman Gitlin; Bradley F Freilich; Ziad H Younes; William Harlan; Reem Ghalib; Godson Oguchi; Paul J Thuluvath; Grisell Ortiz-Lasanta; Mordechai Rabinovitz; David Bernstein; Michael Bennett; Trevor Hawkins; Natarajan Ravendhran; Aasim M Sheikh; Peter Varunok; Kris V Kowdley; Delphine Hennicken; Fiona McPhee; Khurram Rana; Eric A Hughes Journal: Hepatology Date: 2015-03-10 Impact factor: 17.425
Authors: Shivan J Mehta; Jessie Torgersen; Dylan S Small; Colleen P Mallozzi; John D McGreevey; Charles A L Rareshide; Chalanda N Evans; Mika Epps; David Stabile; Christopher K Snider; Mitesh S Patel Journal: JAMA Netw Open Date: 2022-03-01
Authors: Thanh V Kim; Duc H Le; Diem V B Dao; Trang Ngoc Doan Pham; Gary W Mize; Loc T B Phan; Dan X Nguyen; Thi-Thuy-Dung Ngo; Robert G Gish; William M Lee; Amy Trang; Anh N Le; Moon Chen; Hai T Phan; Binh T Nguyen; Hong K Tang; Doan Y Dao Journal: Lancet Reg Health West Pac Date: 2022-07-09